Clinical trials: Post-COVID
Post-COVID-19 Syndrome, Anxiety
Connecting Breath and Mind for CYP With Long COVID
Recruitment target: Phase I: Co-design of intervention: 5 to 15 CYP aged between 12-18 years of age referred to the pan-London long COVID MDT.
- Conditions
- Post-COVID-19 Syndrome, Anxiety, Breathlessness
- Trial name
- NCT05705154
- Testing
- Psychology interventions
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Long COVID-19 Syndrome, Post COVID Syndrome Long Covid
Inspiratory Muscle Pressure and Diaphragmatic Strength in Women With Long COVID-19: A Pressure Biofeedback-Guided Training Study
COVID-19 is an infectious disease that can cause long-term health problems even after the acute infection has resolved. Many people who have recovered from COVID-19 continue to experience breathing difficulties, fatigue, and…
- Conditions
- Long COVID-19 Syndrome, Post COVID Syndrome Long Covid, Post COVID-19 Syndrome
- Trial name
- NCT07397130
- Testing
- Pressure Biofeedback Unit
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- RSUP Persahabatan
COVID-19, Corona Virus Infection
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- C-PIC (NCT04448145)
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Columbia University
Post-acute COVID-19 Syndrome
The Study of Brave-LC LDN Treatment Trial
This is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of a 16-week course of low-dose naltrexone (LDN) in approximately 1,300 participants aged 6 to 25 years with fatigue…
- Trial name
- NCT07916259
- Testing
- naltrexone
- Where
- 13 sites in United States
- Volunteers
- 1,300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
- Trial name
- NCT06333704
- Testing
- SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5
- Where
- 26 sites in South Korea
- Volunteers
- 4,207 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Coronavirus Disease
Post COVID-19 Functional Status in Egypt
Since the outbreak of coronavirus disease - COVID-19 pandemic, most attention has focused on mode of transmission, clinical picture of the disease, treatment and prevention.
- Conditions
- COVID-19, Coronavirus Disease, SARS-CoV-2
- Trial name
- NCT04479293
- Testing
- Post COVID-19 Functional Satus Scale
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Assiut University
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer
Long COVID, Breathlessness
Long COVID and Post-exertional Pulmonary Diffusion
Aim of investigators was to study whether abnormalities of lung diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) in long COVID may have a clinical impact in relation to exercise intolerance.
- Conditions
- Long COVID, Breathlessness, Exercise Intolerance, Alveolar Lung Disease
- Trial name
- Long_COVID_Ex (NCT05430503)
- Testing
- Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise
- Where
- Italy
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
COVID - 19, Diabetes Mellitus
DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN
The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children.
- Conditions
- COVID - 19, Diabetes Mellitus, Post-COVID Conditions, MIS-C Associated With COVID-19
- Trial name
- NCT06784713
- Where
- Estonia
- Volunteers
- 127,277 people
- Sponsor
- University of Tartu
Fever After Vaccination, Fever
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19…
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Trial name
- NCT06038617
- Testing
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Where
- 5 sites in United States
- Volunteers
- 347 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19; and High Infection Risk of SARS-CoV-2
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese…
- Trial name
- NCT04441918
- Testing
- JS016 (anti-SARS-CoV-2 monoclonal antibody)
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Post-COVID Condition
Munich Long COVID Registry for Children, Adolescents, and Adults
The MLC-R aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for Long COVID at any age in Germany, which can be used for future clinical trials.
- Trial name
- MLC-R (NCT05638724)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Technical University of Munich
Post COVID
Vitamine D in Post-COVID Patients
In this study routineously collected vitamine D values will compared to healthy cohorts from this year and previous years.
- Trial name
- VD-PCS (NCT04969237)
- Testing
- Vitamine D in blood samples
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Klinikum Emden
Vaccine Reaction
SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19
Analysis of SARS-CoV-2 antibodies and serum virus neutralisation in vaccinated heath care personnel. Analysis of virus neutralisation as a function of age, gender, and history of COVID-19 infection.
- Trial name
- DER-CoV2-001 (NCT04979871)
- Testing
- Venous bleeding
- Where
- Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Zurich
SARS-CoV-2
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
- Trial name
- NCT06130345
- Testing
- SPIKEVAX
- Where
- United States
- Volunteers
- 15,196,685 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
ME/CFS, CFS/ME
Multi-Center Registry for ME/CFS
The ME/CFS study (MECFS-R) aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for ME/CFS at any age in Germany, which can be used for future clinical…
- Conditions
- ME/CFS, CFS/ME, ME/CFS Following EBV-associated Infectious Mononucleosis, ME/CFS Following COVID-19
- Trial name
- MECFS-R (NCT05778006)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Technical University of Munich
COVID-19, SARS-CoV-2
Secondary Databased Post-marketing Surveillance Study of BNT162b2
This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.
- Trial name
- NCT06743334
- Testing
- Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
- Where
- South Korea
- Volunteers
- 14,302,529 people
- Sponsor
- Pfizer
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.